Evidence mapPaperPMID 40539457Full record

ReviewInternational journal of oncology2025

Protein lactylation and immunotherapy in gliomas: A novel regulatory axis in tumor metabolism (Review).

Tao Luo, Liang Liu, Hao Wang, Shuai Wen

Abstract readReview
In one paragraph

Review in International journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tao LuoDepartment of Neurosurgery, People's Hospital of Ningxiang City, Hunan University of Chinese Medicine, Ningxiang, Hunan 410699, P.R. China.
Liang LiuDepartment of Neurosurgery, People's Hospital of Ningxiang City, Hunan University of Chinese Medicine, Ningxiang, Hunan 410699, P.R. China.
Hao WangDepartment of Neurosurgery, People's Hospital of Ningxiang City, Hunan University of Chinese Medicine, Ningxiang, Hunan 410699, P.R. China.
Shuai WenDepartment of Neurosurgery, People's Hospital of Ningxiang City, Hunan University of Chinese Medicine, Ningxiang, Hunan 410699, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are the most common primary brain tumors, and exhibit highly heterogeneous and aggressive biological behaviors. Metabolic reprogramming is a hallmark of gliomas, and lactate accumulation serves a critical role in tumor progression. In addition to its traditional role as a metabolic byproduct, lactate has been recognized as a signaling molecule that modifies proteins through lactylation, which is a novel post‑translational modification. Lactate‑induced lactylation of histone and non‑histone proteins is emerging as a key epigenetic and metabolic regulator that influences glioma development, immune evasion, angiogenesis and therapeutic resistance. The present review provides mechanistic insights into protein lactylation, its role in glioma progression and its potential therapeutic implications. Targeting lactate metabolism and lactylation‑modifying enzymes holds promise for improving glioma treatment outcomes.

Indexed as

Brain NeoplasmsGliomaImmunotherapyLactic AcidAnimalsHumansProtein Processing, Post-TranslationalLactic AcidgliomasimmunotherapylactylationmetabolismPTMtherapy

Identifiers

PMID40539457
PMCPMC12221121

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.